Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach.

Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Jun 2020

Geerts Hugo, Spiros Athan

Abstract excerpt

BACKGROUND: Many trials of amyloid-modulating agents fail to improve cognitive outcome in Alzheimer's disease despite substantial reduction of amyloid β levels. METHODS: We applied a mechanism-based Quantitative Systems Pharmacology model exploring the pharmacodynamic interactions of apolipoprotein E (APOE), Catechol -O -methyl Transferase (COMTVal158Met), and 5-HT transporter (5-HTTLPR) rs25531 genotypes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Apolipoproteins E

Share to Catechol O-Methyltransferase

Share to Genotype

Share to Models, Biological

Share to Serotonin Plasma Membrane Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 32255562
DOI: 10.1002/alz.12082
PMCID: PMC7983876

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach.PMID 32255562Read ↗

Simulating the Effects of Common Comedications and Genotypes on Alzheimer's Cognitive Trajectory Using a Quantitative Systems Pharmacology Approach.Semantic proximity Read ↗

Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 TreatmentSemantic proximity Read ↗

A data-driven Alzheimer’s disease progression simulator for retrospective validation and prospective Phase III power designSemantic proximity Read ↗

Generate Synthetic Data in R for a Hypothetical Alzheimer’s Disease TrialSemantic proximity Read ↗

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartanSemantic proximity Read ↗

Reducing placebo response in clinical trials of agitation in Alzheimer’s diseaseSemantic proximity Read ↗

Virtual Trials: Causally-validated treatment effects efficiently learned from an observational cancer registrySemantic proximity Read ↗

TPMS technology to infer biomarkers of macular degeneration prognosis in <i>in silico</i> simulated prototype-patients under the study of heart failure treatment with sacubitril and valsartanSemantic proximity Read ↗

Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology ModelsSemantic proximity Read ↗

Simulating the outcome of amyloid treatments in Alzheimer’s disease from imaging and clinical dataSemantic proximity Read ↗

Clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration: a quantitative systems pharmacology model analysisSemantic proximity Read ↗

Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.